Overview

A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI

Status:
Active, not recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

This study aim to investigate the myocardium protection effect of cardiomyopeptidin in patients undergoing primary PCI for ST-elevation myocardial infarction through myocardial enhanced MRI.

Phase:

Phase 4

Details

Lead Sponsor:

Chinese PLA General Hospital

Collaborator:

Dalian Zhen-Ao Bio-Tech Co., Ltd.